Zhu Liqin, Liao Shasha, Wang Nan, Ge Tingyue, Yang Jianwei, Xu Gaoqi, Wang Jianhai, Li Keqiu, Li Guang
Int J Clin Pharmacol Ther. 2016 Aug;54(8):587-96. doi: 10.5414/CP202490.
Genetic polymorphisms of the P450 2C9 enzyme (CYP2C9), CYP2C19 and CYP3A5 gene are known to affect the metabolism of many drugs applied in liver transplant recipients, such as warfarin, voriconazole, and tacrolimus. The aim of this study was to recommend dose regimens for the liver recipients based on CYP2C9, CYP2C19, and CYP3A5 genotypic combinations of liver transplant recipients and their donors.
91 adult Han Chinese liver transplant recipients who underwent orthotopic liver transplantation at Tianjin First Central Hospital, China, between 2013 and 2014 were included in this study. CYP2C92, CYP2C93, CYP2C19* 2, CYP2C193 and CYP3A53, in both liver recipients and their grafted liver were tested by polymerase chain reaction-restriction fragment length polymorphism. The dose regimens for the liver recipients were recommended based on CYP genotypic combinations of the recipients and their donors.
In the liver transplant recipients, the frequencies of CYP2C92, CYP2C93, CYP2C192, CYP2C193, and CYP3A53 were found to be 2.75%, 4.40%, 0%, 24.18%, and 75.27%, respectively. Allele frequencies were significantly different for CYP2C92, CYP2C192, and CYP2C19 3 (p < 0.001) when comparing the recipients with Chinese, Eastern Asians and Caucasians populations. Most dose regimens of drugs, especially of immunosuppressive drugs, should be adjusted according to the variant metabolism activity affected by the genetic polymorphisms in both recipients and their grafted liver.
The dose regimens would present considerable intraand inter-patient variability in liver transplant recipients since the genetic polymorphisms of P450 enzyme in their grafted liver might complicate the metabolism of drugs in liver transplant recipients. Giving careful consideration to the CYP genotypic combinations of transplant recipients and donors in clinical dose regimens could optimize outcomes.
已知细胞色素P450 2C9酶(CYP2C9)、CYP2C19和CYP3A5基因的遗传多态性会影响肝移植受者应用的许多药物的代谢,如华法林、伏立康唑和他克莫司。本研究的目的是根据肝移植受者及其供者的CYP2C9、CYP2C19和CYP3A5基因组合,为肝移植受者推荐给药方案。
本研究纳入了2013年至2014年间在中国天津第一中心医院接受原位肝移植的91例成年汉族肝移植受者。采用聚合酶链反应-限制性片段长度多态性方法检测肝移植受者及其移植肝脏中的CYP2C92、CYP2C93、CYP2C192、CYP2C193和CYP3A5*3。根据受者及其供者的CYP基因组合为肝移植受者推荐给药方案。
在肝移植受者中,CYP2C92、CYP2C93、CYP2C192、CYP2C193和CYP3A53的频率分别为2.75%、4.40%、0%、24.18%和75.27%。与中国人、东亚人和高加索人群相比,CYP2C92、CYP2C192和CYP2C193的等位基因频率有显著差异(p<0.001)。大多数药物的给药方案,尤其是免疫抑制药物,应根据受者及其移植肝脏中遗传多态性影响的代谢活性变异进行调整。
由于肝移植受者移植肝脏中P450酶的遗传多态性可能使肝移植受者的药物代谢复杂化,给药方案在肝移植受者中会呈现出相当大的个体内和个体间变异性。在临床给药方案中仔细考虑移植受者和供者的CYP基因组合可以优化治疗效果。